

# *The Macula Society*

*36th Annual Scientific Program*



*St. Regis Monarch Beach  
Dana Point, California  
February 27 - March 2, 2013*

*The Macula Society  
3401 Enterprise Parkway, Suite 310, Cleveland, Ohio 44122  
(216) 839-4949 Fax: (216) 831-8221  
Email: [maculasociety@aol.com](mailto:maculasociety@aol.com)  
Website: [maculasociety.org](http://maculasociety.org)*



## *Accreditation*

**This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Medical College of Wisconsin and the Macula Society. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.**

The **Medical College of Wisconsin** designates this Live Activity for a maximum of **23.50 AMA PRA Category 1 Credits<sup>TM</sup>**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

# *Table of Contents*

## **Accreditation**

Inside Cover

## **Officers of The Macula Society**

Page 4

## **Registration**

Page 6

## **Social Program**

Page 7

## **Meeting Sponsors**

Page 11

## **2013 Case Conference**

Page 20

## **Scientific Program**

Page 23

## **Abstracts**

Page 39

## **Presenter Index**

Page 332

## **Speaker Disclosures**

Page 336

## *Past Presidents of the Macula Society*

Arnall Patz, MD	1978-80
J. Donald M. Gass, MD	1980-82
Morton F. Goldberg, MD	1982-84
Robert C. Watzke, MD	1984-86
Stephen J. Ryan, MD	1986-88
John G. Clarkson, MD	1988-90
David H. Orth, MD	1990-92
Alexander J. Brucker, MD	1992-94
Lee M. Jampol, MD	1994-96
Thomas M. Aaberg, MD	1996-98
Travis A. Meredith, MD	1998-00
Kurt A. Gitter, MD	2000-02
William F. Mieler, MD	2002-04
Daniel Finkelstein, MD	2004-06
Lawrence A. Yannuzzi, MD	2006-08
Evangelos S. Gragoudas, MD	2008-09
Jerry A. Shields, MD	2009-10
Michael L. Klein, MD	2010-11
Emily Y. Chew, MD	2011-12

## *Officers of The Macula Society June 2012 – March 2013*

Mark S. Blumenkranz, MD	President
Lawrence J. Singerman, MD	Executive Secretary
Neil M. Bressler, MD	President-Elect
Paul Sternberg, Jr., MD	Secretary
M. Gilbert Grand, MD	Treasurer
Emily Y. Chew, MD	Immediate Past President

# *Committees of The Macula Society*

## *June 2012 – March 2013*

### **Awards Committee**

Michael L. Klein, MD *Chair*  
Mark S. Blumenkranz, MD  
Lawrence J. Singerman, MD  
Emily Y. Chew, MD

### **By-Laws Committee**

SriniVas Sadda, MD *Chair*  
Mark S. Blumenkranz, MD  
Lawrence J. Singerman, MD  
Gaurav K. Shah, MD  
Szilárd Kiss, MD

### **Credentials Committee**

Carol Shields, MD *Chair*  
Lawrence J. Singerman, MD  
Mark S. Blumenkranz, MD  
Dennis Han, MD  
Craig M. Greven, MD  
Mary Elizabeth Hartnett, MD  
Harry W. Flynn, MD  
Herbert Cantrill, MD  
Usha Chakravarthy, MD  
Serge de Bustros, MD

### **Meeting Planning Committee**

Robert A. Braunstein, MD, MBA  
*Chair*  
Mark S. Blumenkranz, MD  
Emily Y. Chew, MD

### **Nominating Committee**

James C. Folk, MD *Chair*  
Lawrence J. Singerman, MD  
Mark S. Blumenkranz, MD  
Stephen R. Russell, MD  
Gary E. Fish, MD

### **Program Committee**

Daniel F. Martin, MD *Chair*  
Lawrence J. Singerman, MD  
Mark S. Blumenkranz, MD  
Judy E. Kim, MD

### **Research and Education Committee**

Jennifer I. Lim, MD *Chair*  
Mark S. Blumenkranz, MD  
Lawrence J. Singerman, MD  
Lloyd P. Aiello, MD, PhD  
Usha Chakravarthy, MD  
Christina J. Flaxel, MD  
Richard F. Spaide, MD  
Cynthia A. Toth, MD

### **Web Site Committee**

Mathew W. MacCumber,  
MD, PhD *Chair*  
David N. Zacks, MD, PhD  
Judy E. Kim, MD  
Jennifer I. Lim, MD  
Lawrence J. Singerman, MD  
Mark S. Blumenkranz, MD

### **AAO Representative**

Michael J. Elman MD

### **International Member Representative**

Anat Loewenstein, MD *Chair*  
Usha Chakravarthy, MD

### **Young Member Representative**

Rajendra S. Apte, MD, PhD

## *Registration*

**Wednesday, February 27, 2013**

10:30 a.m.-7:00 p.m.

**Thursday, February 28, 2013**

6:30 a.m.-1:00 p.m.

**Friday, March 1, 2013**

6:30 a.m.-5:30 p.m.

**Saturday, March 2, 2013**

6:30 a.m.-1:00 p.m.

## *Speaker Ready Room – Sorrento Room*

**Wednesday, February 27, 2013**

10:30 a.m.-7:00 p.m.

**Thursday, February 28, 2013**

6:30 a.m.-1:30 p.m.

**Friday, March 1, 2013**

6:30 a.m.-5:30 p.m.

**Saturday, March 2, 2013**

6:30 a.m.-1:30 p.m.

## *Meetings*

**Executive Committee**

Wednesday, February 27, 2013

12:00 p.m.-2:00 p.m.

Adriatic Room

**Annual Business Meeting (Members Only)**

Friday, March 1, 2013

6:30 a.m.-7:30 a.m.

Grand Ballroom I and II

## *Young Member Mentor Lecture*

**Guest Speaker: Paul Sternberg Jr., MD**

**Guest Speaker: J. William Harbour, MD**

Thursday, February 28, 2013

6:30 a.m.-7:30 a.m.

Mediterranean Room

with support from Regeneron

# *Scientific Program*

## *Case Study Conference Grand Ballroom*

**Wednesday, February 27, 2013**

2:00 p.m.-5:00 p.m.

## *General Sessions Grand Ballroom*

**Wednesday, February 27, 2013**

5:00 p.m.-6:36 p.m.

**Thursday, February 28, 2013**

7:30 a.m.-1:22 p.m.

**Friday, March 1, 2013**

7:30 a.m.-12:30 p.m.

2:00 p.m.-4:56 p.m.

**Saturday, March 2, 2013**

7:30 a.m.-12:42 p.m.

# *Social Program*

**Wednesday, February 27, 2013**

## *Welcome Buffet Dinner,*

Motif Terrace and Motif Restaurant

7:00 p.m.-10:00 p.m.

Attire: Business casual

**February 28, March 1-2, 2013**

Thursday through Saturday

## *Breakfast Buffet for all attendees*

6:30 a.m.-10:00 a.m.

Ballroom III

**Friday, March 1, 2013**

# *36th Annual Macula Society Gala*

## *Cocktails*

7:30 p.m.

Pacific Lawn Rotunda

## *Gala Dinner Reception*

8:15 p.m.

Grand Ballroom I and II

Attire: Cocktail attire

# 2013 Awards

## *Presentation of 2012 J. Donald M. Gass Medal*

**Thursday, February 28, 2013 12:50 p.m.**

*Recipient: Frederick L. Ferris, III, MD*

*Presenter: Emily Y. Chew, MD*

## *Presentation of 2013 J. Donald M. Gass Medal*

**Thursday, February 28, 2013 12:58 p.m.**

*Recipient: William F. Mieler, MD*

*Presenter: Jennifer J. Kang-Mieler, MD*

## *Green Lecture and Award*

**Thursday, February 28, 2013 1:06 p.m.**

*“The Evolution of Geographic Atropohy”*

*Recipients: John Sarks, FRCS, FRANZCO and*

*Shirley Sarks, FRCS, FRANZCO, MD*

*Presenter: Alan Bird, MD*

## *Evangelos S. Gragoudas Award*

**Friday, March 1, 2013 9:38 a.m.**

*Recipient: Ruwan Amila Silva, MD*

*Presenter: Darius Moshfeghi, MD*

## *Young Investigator Award and Lecture*

**Friday, March 1, 2013 9:46 a.m.**

*“ ‘Eyeball’-ing the Immune System”*

*Recipient: Rajendra S. Apte, MD, PhD*

*Presenter: J. William Harbour, MD*

## *Young Investigator Award and Lecture*

**Friday, March 1, 2013 10:04 a.m.**

*Recipient: Michael D. Abramoff, MD, PhD*

*Presenter: James C. Folk, MD*

## *Arnall Patz Medal*

**Friday, March 1, 2013 11:58 a.m.**

*Recipient: Peter A. Campocharo, MD*

*Presenter: Neil M. Bressler, MD*

## *Paul Henkind Memorial Lecture and Award*

**Friday, March 1, 2013 12:06 p.m.**

*“Lifecycle of Pseudodrusen”*

*Recipient: Richard F. Spaide, MD*

*Presenter: Alexander J. Brucker, MD*



*The  
Macula Society*

gratefully acknowledges  
the support of

The Mills and Margaret Cox  
Macula Society Research Project

sponsored by

*Retina Research Foundation*

from an RRF endowment  
established by the Cox Estate

Alice R. McPherson, MD  
President  
Retina Research Foundation  
Houston, Texas

*The  
Macula Society*

would like to thank

*Larry Yannuzzi, MD*

and the

*Macula Foundation*

for their continuing support of the  
Paul Henkind Memorial Lecture

*The  
Macula Society*

wishes to thank the  
following  
companies for their  
support of the  
2013  
Annual Meeting

*The  
Macula Society  
extends a special  
thanks to  
this year's  
Major Meeting  
Sponsor . . .*

**Genentech**

*A Member of the Roche Group*

*Major Meeting Sponsor*

---

**Genentech**

*A Member of the Roche Group*

One DNA Way

South San Francisco,

California 94080

*www.gene.com*

# Ruby Patrons

---



## **REGENERON**

O P H T H A L M O L O G Y

***science to medicine™***

For more information:  
Call 1-855-395-3248, Monday-Friday  
9AM-8PM Eastern Time and select option 4 to begin

[www.regeneron.com](http://www.regeneron.com)

©2013, Regeneron Pharmaceuticals, Inc.  
RGN-0065 1/2013

Printed in the USA

All rights reserved

*Sapphire Patrons*

---

**Alcon**<sup>®</sup>

**ALCON LABORATORIES, INC.**

6201 South Freeway  
Fort Worth, Texas 76134

Phone: (817) 551-4520  
Fax: (817) 302-3781

*www.alconlabs.com*

SAPPHIRE PATRONS

 **ALLERGAN**  
**Retina**

LET'S ENVISION  
*the* FUTURE TOGETHER

Allergan Retina  
2525 Dupont Drive, Irvine, CA 92612  
PHONE: 1-714-246-4500 FAX: 1-714-246-4971 [www.allergan.com](http://www.allergan.com)

©2013 Allergan, Inc., Irvine, CA 92612 APC76YM13 130375

*Topaz Patrons*

---

# Lumenis



# *Garnet Patrons*

---

**ArcticDx, Inc.**  
101 College Street, Suite 335  
Toronto, ON Canada M5G 1L7  
(866) 964-5182

**HEIDELBERG  
ENGINEERING**

800-931-2230  
[www.HeidelbergEngineering.com](http://www.HeidelbergEngineering.com)

© 2013 Heidelberg Engineering, Inc. All rights reserved.

**Santen**

2100 Powell Street, 16th Floor  
Emeryville, California 94608  
Mike Ford, Director  
(415) 268-9058  
[www.santeninc.com](http://www.santeninc.com)

 **SEQUENOM<sup>®</sup>CMM<sup>®</sup>**  
CENTER FOR MOLECULAR MEDICINE

**Lorah Perlee**  
Vice President, Scientific Affairs, Sequenom  
3595 John Hopkins Court, San Diego, CA 92121  
Tel: 877-721-7266 • [www.SequenomCMM.com](http://www.SequenomCMM.com)

# *Amethyst Patrons*

---

## **OPTOS, INC.**

Company Representative:  
Dana Keane  
Phone: (800) 854-3039 x1507  
Email: [dkeane@optos.com](mailto:dkeane@optos.com)  
[www.optos.com](http://www.optos.com)

## **CARL ZEISS MEDITEC**

5160 Hacienda Drive  
Dublin, CA 95468  
Kevin Langton  
Phone: (917) 623-8515  
[www.meditec.zeiss.com/us](http://www.meditec.zeiss.com/us)

## **OPTOVUE**

2800 Bayview Drive  
Fremont, California 94538  
Phone: (510) 623.8868  
Fax: (510) 623.8668  
[www.optovue.com](http://www.optovue.com)

# *The Macula Society*

## Additional 2013 Corporate Sponsors

### *Topaz Patrons*

---



**JETREA™**

(ocriplasmin)  
Intravitreal Injection, 2.5 mg/mL

**NOW AVAILABLE**

VISIT **JETREACARE.COM** FOR REIMBURSEMENT AND ORDERING INFORMATION

ThromboGenics, Inc. 02/13 OCRVMA0068 MAC

**Lumenis Vision  
is the World  
Leader in Laser  
Technologies  
for Ophthalmic  
Applications.**

For an authorized  
Lumenis representative  
in your country,  
please visit:  
**www.lumenis.com**  
(click on "contact us")

Or email us at:  
information@lumenis.com

 **LUMENIS®**  
Enhancing Life. Advancing Technology.

# *The Macula Society*

Additional 2013 Corporate Sponsors

## *Garnet Patrons*

---



# **Arctic**

GROUP OF COMPANIES

## **ForeseeHome™**

AMD Monitoring Program

by Notal Vision™

(877) 322-2207

[www.foreseehome.com](http://www.foreseehome.com)

## *Amethyst Patrons*

---

### **ALIMERA SCIENCES, INC.**

6120 Windward Parkway, Suite 290

Alpharetta, GA 30005

Antonio Cutino – 678-527-1322

### **IRIDEX**

1212 Terra Bella Avenue

Mt. View, CA 94043

P: 650-940-4700

EM:[info@iridex.com](mailto:info@iridex.com)

URL:[www.iridex.com](http://www.iridex.com)

### **VALEANT OPHTHALMICS**

C. David Green

700 Route 202/206 North

Bridgewater, NJ 08807

phone: 908-927-1824

fax: 908-927-1424

### **BAUSCH + LOMB**

*Russ Finlay*

(585) 338-5903

[www.bausch.com](http://www.bausch.com)

# *Macula Society* *2013 Case Conference*

WEDNESDAY, FEBRUARY 27, 2013  
SESSION I

## *Imaging and Case Study Conference*

**2:00 - 3:20 p.m. Moderators: Lee Jampol  
Mathew MacCumber**

- 2:00 Jose Pulido  
Beyond the Visible
- 2:05 Robert Johnson  
Birdshot Lesions in a Patient Without Birdshot
- 2:10 Lee Jampol  
CAR or Drug Toxicity
- 2:15 Salomon Cohen  
One Condition or Two?
- 2:20 Anita Leys  
Paraneoplastic Melanocytic Proliferation Treated with  
Plasmapheresis
- 2:25 Antonio Ciardella  
Mystery Case
- 2:30 Daniel Roth  
Acute Exudative Polymorphous Vitelliform Maculopathy in a  
Young Man
- 2:35 Mathew MacCumber  
Central Serous Chorioretinopathy or Age-Related Macular  
Degeneration?
- 2:40 Ayala Pollack  
Too Much Light can be Blinding
- 2:45 Stephen Schwartz  
H is for . . . ?
- 2:50 Jerry Shields  
Hearing Loss and a Fundus Lesion
- 2:55 Michael Goldbaum  
Spontaneous Massive Uveal Effusion

# *Macula Society* *2013 Case Conference*

WEDNESDAY, FEBRUARY 27, 2013

**continued**

- 3:00 Thomas Friberg  
Silicone Oil and Peripheral Vascular Leakage After Retinal Detachment Repair
- 3:05 Rishi Singh  
8-Ball Hyphema Following Intravitreal Injection of Ranibizumab for Branch Retinal Vein Occlusion
- 3:10 Gaetano Barile  
Unilateral Central Visual Loss
- 3:15 Carol Shields  
Dangerous Floaters

## **SESSION II**

**3:20 - 4:55 p.m. Moderators: Anita Agarwal  
Larry Yannuzzi**

- 3:20 Quan Nguyen  
Yet . . . Another Case of White and Not-So-White Dots
- 3:25 Caroline Bauml  
Acute Macular Neuroretinopathy
- 3:30 Vishali Gupta  
Mystery Case
- 3:35 Graham Holder  
A Patient with Unusual Fundus Autofluorescence Imaging
- 3:40 David Sarraf  
Mystery Case
- 3:45 Shree Kurup  
Value of the Retinal Examination After Non-Contributory Multiple Invasive Procedures over 8 Months in a 15-year-old
- 3:50 David Weinberg  
Vision Loss in a Young Woman

# *Macula Society* *2013 Case Conference*

WEDNESDAY, FEBRUARY 27, 2013

**continued**

- 3:55 Arun Singh  
Unusual Intraocular Tumor
- 4:00 Tara McCannel  
Macular Pucker with Intraocular Tumor
- 4:05 Michaela Goldstein  
Choroidal Nevus and . . .
- 4:10 Giovanni Staurengi  
Retinoschisis in Diabetic Retinopathy
- 4:15 J. William Harbour  
Intraocular Mass
- 4:20 William Mieler  
Mystery Case
- 4:25 Michael Singer  
A Case of Recalcitrant CSR
- 4:30 Colin McCannel  
Static Pressure and Pascal's Law Meet the Retina
- 4:35 Shlomit Schaal  
Central Retinal Artery Occlusion Post Partum: Clinical  
Presentation of Potentially Deadly Predominantly Female  
Disorder
- 4:40 Alexander Brucker  
Retinal Structure in Vitamin A Deficiency as Revealed with  
Spectral Domain Optical Coherence Tomography
- 4:45 Anita Agarwal  
Unusual Distribution of Multifocal Vitelliform Lesions
- 4:50 Lawrence Yannuzzi  
Multifocal Choroiditis

2013  
*Scientific Program*

Wednesday through Saturday

February 27 – March 2, 2013  
Dana Point, California

The eight minutes allotted for each presentation consists of six minutes for presentation and two minutes for discussion with the audience.



# WEDNESDAY, FEBRUARY 27, 2013

## SESSION I

### Imaging

*Moderator: Richard Rosen*

*Moderator: Giovanni Staurenghi*

- 5:00 p.m. Fluoro Microangiography – First Clinical Studies of Fluorescein Angiography using Adaptive Optic Scanning Laser Ophthalmoscopy  
*Richard Rosen*
- 5:08 p.m. Hyperreflective OCT Spots as Biomarker of Microglial Activation in the Retina of Diabetics Without and With Early Retinopathy  
*Edoardo Midena*
- 5:16 p.m. Equations to Convert Retinal Thickness Measurements from Spectral Domain OCT Machines to “Equivalent” Time Domain OCT Measurements  
*Dennis Marcus*
- 5:24 p.m. Topographical Analyses of Tilted Disc Syndrome by using 3D MRI and Swept-Source OCT  
*Kyoko Obno-Matsui*
- 5:32 p.m. Diurnal Variation of Macular Choroidal Volume in Healthy Volunteers  
*Libteh Wu*
- 5:40 p.m. Choroidal Thickness in Adult Onset Foveomacular Vitelliform Dystrophy versus Dry and Exudative Age-Related Macular Degeneration  
*Gabriel Coscas*
- 5:48 p.m. Pilot Study of Choroidal Vascular Quantification Using En Face OCT  
*Amani Fawzi*
- 5:56 p.m. “En face” OCT Imaging in Type 2 Idiopathic Macular Telangiectasia  
*Martine Mauget-Fajisse*
- 6:04 p.m. Studying the Progression of Retinal Vascular Changes Associated with Macular Telangiectasia in 3-Dimension using Power-doppler OCT  
*Susanna Park*

- 6:12 p.m. Assessing the Reliability and Repeatability of a Commercially Available Flood-Illuminated Adaptive Optics Camera – Is it Ready for Clinical Trials?  
*Mark Pennesi*
- 6:20 p.m. The Photobleaching Effect in Evaluation of Fundus Autofluorescence  
*Giovanni Staurenghi*
- 6:28 p.m. A Novel High-Speed and High Resolution Optical Coherent Tomography: a Preliminary Report  
*Shin Yoneya*
- 6:36 p.m. **End of Session**

## THURSDAY, FEBRUARY 28, 2013

### SESSION II

#### Dry AMD

*Moderator: Phil Rosenfeld*

*Moderator: Nancy Holekamp*

- 7:30 a.m. Rod-Mediated Dark Adaptation as a Functional Outcome Measure in the Study of Age-Related Macular Degeneration  
*Catherine Cukras*
- 7:38 a.m. The Role of the Choroidal Thickness in Determining Scotopic and Photopic Sensitivities in Various Stages of Age-Related Macular Degeneration (AMD)  
*Karl Csaky*
- 7:46 a.m. Reticular Genetics Update  
*R. Theodore Smith*
- 7:54 a.m. Genetic Analysis of Concordant Versus Discordant Age-Related Macular Degeneration  
*Stephen Schwartz*
- 8:02 a.m. A Comparison of Two Commercially Available Genetic Tests for Age-Related Macular Degeneration  
*Nancy Holekamp*
- 8:10 a.m. Complement Factor H Genotype in Atrophic and Neovascular AMD: Implications for Pathophysiology and Genetic Testing  
*Robert Mullins*
- 8:18 a.m. Value of Genetic and Clinical Features in Predicting Progression to Advanced Age-Related Macular Degeneration (AMD)  
*Franco Recchia*

- 8:26 a.m. Subclassification of AMD Patients Based on Metabolic Characteristics  
*Milam Brantley*
- 8:34 a.m. Periodontal Disease and Age-Related Macular Degeneration  
*Jorge Arroyo*
- 8:42 a.m. NSAID Use and Risk of Age-Related Macular Degeneration  
*Donald Fong*
- 8:50 a.m. Progression of Geographic Atrophy in the COMPLETE Study  
*Philip Rosenfeld*

**SESSION III**  
**Neovascular AMD I**

*Moderator: Allen Ho*

*Moderator: Usba Chakravarthy*

- 8:58 a.m. Analysis of Single Nucleotide Polymorphisms Profile for Eyes with Vascularized Pigment Epithelial Detachment due to AMD  
*Clement Chan*
- 9:06 a.m. Peripapillary Pigmentary Changes in Neovascular Age-Related Macular Degeneration (nAMD)  
*Salomon Cohen*
- 9:14 a.m. The Composition of the Vitreous Proteome in Patients with Wet AMD Can Differentiate Between CNV and RAP: An Important New Diagnostic Tool  
*Bert Glaser*
- 9:22 a.m. Optical Coherence Tomography and Fluorescein Angiography in the Diagnosis of New-onset Neovascular Age-Related Macular Degeneration. A Comparative Study  
*Alain Gaudric*
- 9:30 a.m. Multilayered Pigment Epithelial Detachment: A New OCT Finding in Neovascular AMD  
*David Sarraf*
- 9:38 a.m. Lesion Reflectivity as a Parameter for Assessment of Disease Activity in Eyes With Neovascular Age-Related Macular Degeneration  
*SriniVas Sadda*
- 9:46 a.m. The HARBOR Study 2-Year Results: Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Wet Age-Related Macular Degeneration  
*Allen Ho*

- 9:54 a.m. Early vs. Delayed 15-Letter Responders to Ranibizumab Treatment in Year 1 of the HARBOR Study  
*Gregg Kokame*
- 10:02 a.m. Association of Best-corrected Visual Acuity (BCVA) Gains at Month 12 in HARBOR with Change in Choroidal Neovascularization (CNV) Area from Baseline  
*Paul Tornambe*
- 10:10 a.m. Association of Baseline Lesion Size with Best-Corrected Visual Acuity (BCVA) at Month 12 in Ranibizumab Studies  
*Anthony Adamis*
- 10:18 a.m. Effectiveness of Quarterly Versus Monthly Ranibizumab According to Initial Response in Visual Acuity – An Analysis of 12 Month Data from the EXCITE Study  
*Victor Chong*
- 10:26 a.m. Serious Adverse Events in the IVAN Trial  
*Usba Chakravarthy*
- 10:34 a.m. **Break**

#### SESSION IV Neovascular AMD II

*Moderator: G. Baker Hubbard*

*Moderator: John Thompson*

- 10:42 a.m. Short-term Outcomes of Aflibercept for Neovascular Age-Related Macular Degeneration in Eyes Previously Treated with Other Vascular Endothelial Growth Factor Inhibitors  
*G. Baker Hubbard, III*
- 10:50 a.m. Conversion to Aflibercept for Refractory or Recurrent Neovascular Age-Related Macular Degeneration  
*John Loewenstein*
- 10:58 a.m. Fluid Status at Week 12 and its Correlation with Fluid Status at Week 52 Following Intravitreal Aflibercept Injections (IAI) in the VIEW Study of wAMD Patients  
*Darius Moshfeghi*
- 11:06 a.m. Daily OCT Examination After First Intravitreal Anti-VEGF Injection: Implication for Drug Pharmacokinetics  
*Michel Farah*
- 11:14 a.m. Impact of the Vitreous Condition on the Efficacy of Antiangiogenic Therapy  
*Ursula Schmidt-Erfurth*

- 11:22 a.m. Prospective Audit of Outcomes of Treatment of Exudative Macular Degeneration: The Fight Retinal Blindness Project  
*Mark Gillies*
- 11:30 a.m. Long-term Visual Acuity Stability in Eyes Treated with Anti-VEGF Therapy for Choroidal Neovascularization Associated with Macular Degeneration  
*John Thompson*
- 11:38 a.m. Photodynamic Therapy, Anti-Vascular Endothelial Growth Factor Therapy, and Combination Therapy for Polypoidal Choroidal Vasculopathy  
*Hyoung Jun Kob*
- 11:46 a.m. A Prospective Study of Treatment Pattern and 12-Month Outcomes of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians  
*Gemmy Cheung*
- 11:54 a.m. Two-Year Results of Combined Intravitreal Ranibizumab and Photodynamic Therapy for Polypoidal Choroidal Vasculopathy  
*Tomohiro Iida*
- 12:02 p.m. Ranibizumab Versus Verteporfin Photodynamic Therapy in the Treatment of Choroidal Neovascularization Secondary to Myopia  
*Tien Wong*
- 12:10 p.m. Choroidal Neovascularization Associated with Acquired Vitelliform Lesions  
*Itay Chowers*
- 12:18 p.m. A Phase 2b Study of E10030, a Platelet Derived Growth Factor (PDGF) Inhibitor in Combination with a Vascular Endothelial Growth Factor (VEGF) Inhibitor for Neovascular Age-Related Macular Degeneration (AMD)  
*Pravin Dugel*
- 12:26 p.m. First in-Human Results of a Refillable Drug Delivery Implant Providing Sustained Release of Ranibizumab in Patients with Neovascular AMD  
*Eugene de Juan Jr.*
- 12:34 p.m. Stereotactic Radiotherapy for Neovascular Age-Related Macular Degeneration: Incidence and Impact of Microvascular Changes in the INTREPID Study  
*Jason Slakter*
- 12:42 p.m. The Pathways to Death: Apoptosis, Pyroptosis, Necroptosis, and Autophagy  
*Joan Miller*

- 12:50 p.m. **Presentation of the 2012 J. Donald M. Gass Medal**  
*Recipient: Frederick L. Ferris, III, MD*  
*Presenter: Emily Y. Chew, MD*
- 12:58 p.m. **Presentation of the 2013 J. Donald M. Gass Medal**  
*Recipient: William F. Mieler, MD*  
*Presenter: Jennifer J. Kang-Mieler, MD*
- 1:06 p.m. **Presentation of the Green Lecture and Award**  
 “The Evolution of Geographic Atrophy”  
*Recipient: John Sarks, FRCS, FRANZCO and*  
*Shirley Sarks FRCS, FRANZCO, MD*  
*Presenter: Alan Bird MD*
- 1:22 p.m. **End of Session**

## FRIDAY, MARCH 1, 2013

### SESSION V

#### Diabetic Retinopathy

*Moderator: Neil Bressler*

*Moderator: Philip Hykin*

- 7:30 a.m. Presenting and Best-corrected Visual Acuity in U.S. Adults with Diabetic Retinopathy: Findings from the 2005-2008 National Health and Nutrition Examination Survey  
*Neil Bressler*
- 7:38 a.m. Implications of Far Peripheral Retinal Lesions Identified on Ultra-wide-field Imaging for Progression of Diabetic Retinopathy  
*Lloyd Paul Aiello*
- 7:46 a.m. Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt vs. Deferred Laser Treatment: 3-year Randomized Trial Results  
*Michael Elman*
- 7:54 a.m. Impact of Ranibizumab Through 36 Months on Patient-Reported Visual Function for Individuals with Diabetic Macular Edema Participating in RESTORE Extension Study  
*Susan Bressler*
- 8:02 a.m. Risk Factors for Worsening of Diabetic Retinopathy During Monthly Anti-VEGF Treatment in RIDE and RISE  
*Jennifer Sun*

- 8:10 a.m. Real-World Utilization of Anti-VEGFs in Diabetic Macular Edema and Retinal Vein Occlusion: Injection Frequency, Patient Monitoring, and Concomitant Therapy Use  
*Szilárd Kiss*
- 8:18 a.m. The European Vitreo-Retinal Society Macular Edema Study  
*Ron Adelman*
- 8:26 a.m. The LUCIDATE Study: A Randomised Clinical Trial to Evaluate the Long-Term Functional and Anatomical Effects of Repeated Ranibizumab Administration Compared with Laser in Diabetic Macular Edema  
*Philip Hykin*
- 8:34 a.m. Multicenter Evaluation of Navigated Laser to Reduce Anti-VEGF Injection Frequency in Diabetic Macular Edema (DME)  
*William Freeman*
- 8:42 a.m. Is There a Systemic Risk of Intravitreal Anti-VEGF Therapy in Certain Patient Populations?  
*Robert Avery*
- 8:50 a.m. Treatment Response to Novel Laser Protocol (OCT-guided selective focal laser) for Diabetic Macular Edema  
*Oh Kwon*
- 8:58 a.m. Randomized Clinical Trial Evaluating Intravitreal Ranibizumab or Intravitreal Saline for Vitreous Hemorrhage from Proliferative Diabetic Retinopathy  
*Kenneth Diddie*

## SESSION VI

### Endophthalmitis After Intravitreal Injection

*Moderator: Stephan Michels*

*Moderator: Sunir Garg*

- 9:06 a.m. Endophthalmitis After Intravitreal Injections: Office-Based Setting and Operating Room Setting  
*Francesco Boscia*
- 9:14 a.m. Performed in the Operating Room: a Retrospective Multicenter Study  
*Stephan Michels*
- 9:22 a.m. Bacterial Cultures in Endophthalmitis Following Intravitreal Injection Compared to Pars Plana Vitrectomy  
*Sunir Garg*
- 9:30 a.m. Fungal Endophthalmitis Outbreak from a Compounding Pharmacy: Implications for Fungal Meningitis  
*Kent Small*

- 9:38 a.m. **Presentation of Evangelos S. Gragoudas Award**  
*Recipient: Ruwan Amila Silva, MD*  
*Presenter: Darius Moshfeghi, MD*
- 9:46 a.m. **Young Investigator Award and Lecture Presentation**  
*Recipient: Rajendra S. Apte, MD, PhD*  
*Presenter: J. William Harbour, MD*
- 10:04 a.m. **Young Investigator Award and Lecture Presentation**  
*Recipient: Michael D. Abramoff, MD, PhD*  
*Presenter: James C. Folk, MD*
- 10:22 a.m. **Break**

**SESSION VII**  
**Vascular Occlusions**

*Moderator: David Boyer*

*Moderator: Peter Campochiaro*

- 10:30 a.m. Morphological Changes of Major Retinal Vessels in Eyes with Acute Branch Retinal Vein Occlusion  
*Akitaka Tsujikawa*
- 10:38 a.m. Association of Outer Retinal Layer Morphology with Visual Acuity in Patients with Retinal Vein Occlusion  
*Ingrid Scott*
- 10:46 a.m. Development of Venous Collaterals in the SCORE Study  
*David Weinberg*
- 10:54 a.m. Collateral Vessel Presence in Branch and Central Retinal Vein Occlusions: Impact on Visual Acuity  
*Rishi Singh*
- 11:02 a.m. Comparative Efficacy of Vascular Endothelial Growth Factor (Vegf) Neutralization in the Treatment of Isovolumetric Macular Edema Secondary to Retinal Vein Occlusion (RVO), Exudative Age-Related Macular Degeneration (exAMD) and Diabetic Retinopathy (DR)  
*Tongalp Tezel*
- 11:10 a.m. Effect of Alternate Ranibizumab Dosing Regimens on Visual and Anatomic Outcomes in Patients with Retinal Vein Occlusion – The SHORE Study  
*Robert Johnson*
- 11:18 a.m. Comparison of Bevacizumab Versus Ranibizumab for the Initial Reduction of Central Macular Thickness in Patients with Retinal Vein Occlusions  
*Michael Singer*



- 11:26 a.m. Intravitreal Aflibercept Injection (IAI) for Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO): Results of COPERNICUS 2-Year and GALILEO 18-Month  
*David Boyer*
- 11:34 a.m. Retrospective Study of Two or More Dexamethasone Intravitreal Implant 0.7 mg Injections for Retinal Vein Occlusion  
*Daniel Roth*
- 11:42 a.m. Progression of Retinal Nonperfusion in Patients with Retinal Vein Occlusion  
*Peter Campochiaro*
- 11:50 a.m. Capillary Non-Perfusion in Pre-Proliferative (Ischemic) CRVO Treated with Ranibizumab in the RAVE (Rubeosis Anti-VEGF) Trial  
*David Brown*
- 11:58 a.m. **Presentation of Arnall Patz Medal**  
*Recipient: Peter A. Campochiaro, MD*  
*Presenter: Neil M. Bressler, MD*
- 12:06 p.m. **Paul Henkind Memorial Lecture and Award Presentation**  
*Recipient: Richard F. Spaide, MD*  
*Presenter: Alexander J. Brucker, MD*
- 12:30 p.m. **Break**

## SESSION VIII

### Uveitis and Tumors I

*Moderator: Carol Shields*

*Moderator: J. William Harbour*

- 2:00 p.m. Confusion Concerning Unilateral Retinal Pigment Epithelial Dysgenesis  
*H. Richard McDonald*
- 2:08 p.m. Ophthalmic Artery Chemosurgery for Retinoblastoma Prevents New Intraocular Tumors  
*David Abramson*
- 2:16 p.m. Retinal Vasoproliferative Tumors In Patients with Neurofibromatosis. An Analysis of 5 Patients  
*Jerry Shields*
- 2:24 p.m. Potential Pitfalls in Measuring the Thickness of Small Choroidal Melanocytic Tumors With Ultrasonography  
*K. Bailey Freund*

- 2:32 p.m. Diffuse Versus Non-Diffuse Small (<3 Millimeters Thickness) Choroidal Melanoma: Comparative Analysis in 1751 Cases  
*Carol Shields*
- 2:40 p.m. The Effect of Clinical Risk Factors on Time to Metastasis in Patients with Uveal Melanoma Treated with Proton Therapy  
*Evangelos Gragoudas*
- 2:48 p.m. Visual Outcomes after Proton Beam Irradiation for Choroidal Melanomas Involving the Macula: Effect of Radiation Dose Reduction  
*Ivana Kim*
- 2:56 p.m. Preventing Neovascular Glaucoma in Uveal Melanoma with Ischemic Retinal Detachment by Associating Anti-VEGFs to Proton Therapy  
*Leonidas Zografos*
- 3:04 p.m. Outcomes of Plaque with Vitrectomy and Silicone Oil in Choroidal Melanoma  
*Tara McCannel*
- 3:12 p.m. Association Between Genetic Mutations and Clinical Outcomes in Uveal Melanoma  
*J. William Harbour*
- 3:20 p.m. Ocular Lymphocytosis and Sarcoidosis as a Paraneoplastic Manifestation of Systemic Cancer  
*Jose Pulido*
- 3:28 p.m. Uveal Lymphoma: Diagnostic Features  
*Arun Singh*

## SESSION IX

### Uveitis and Tumors II

*Moderator: Robert Nussenblatt*

*Moderator: James Folk*

- 3:36 p.m. Fundus Autofluorescence Patterns in Patients with Primary Vitreoretinal Lymphoma  
*Robert Nussenblatt*
- 3:44 p.m. Advanced Coats' Disease Treated with Intravitreal Bevacizumab Combined with Indirect Laser Vascular Ablation  
*Timothy Murray*
- 3:52 p.m. Fluorescein Angiography-Guided Laser Treatment in Coats' Disease and Familial Exudative Vitreoretinopathy  
*Audina Berrocal*

- 4:00 p.m. Ocular Complications in Patients with Plasma Cell Dyscrasia and Light Chain Deposition Disease (LCDD)  
*Anita Leys*
- 4:08 p.m. Autoimmune Retinopathy: Clinical Features and Prognosis  
*H. Nida Sen*
- 4:16 p.m. AZOOR: Revisited  
*Lawrence Yannuzzi*
- 4:24 p.m. Clinical Profile of Acute Zonal Occult Outer Retinopathy (AZOOR)  
*Anita Agarwal*
- 4:32 p.m. Spectral Domain-Optical Coherence Tomography Findings in Acute Syphilitic Posterior Placoid Chorioretinopathy  
*Antonio Ciardella*
- 4:40 p.m. Activated Histoplasmosis Scars  
*James Folk*
- 4:48 p.m. Is it Advanced Posterior Uveitis or End Stage Disease: Who do you not Treat? Multiple Case Scenarios with Three-Year Follow-up Analyzed by an Expert Panel  
*Shree Kurup*
- 4:56 p.m. 12-Month Results of the SAVE Study - Sirolimus as Therapeutic Approach to Uveitis: A Randomized Study to Assess the Safety and Bioactivity of Intravitreal and Subconjunctival Injections of Sirolimus in Patients with Non-infectious Uveitis  
*Quan Nguyen*

## SATURDAY, MARCH 2, 2013

### SESSION X

#### Basic Science/AMD and Diabetic Retinopathy

*Moderator: Sophie Bakri*

*Moderator: Kim Drenger*

- 7:30 a.m. Subretinal Drusenoid Deposit: The Other Half of AMD Pathology  
*Christine Curcio*
- 7:38 a.m. The Role of P38 in the Regulation of RPE Cell-Cycle as a Model for Dry AMD  
*Ayala Pollack*

- 7:46 a.m. A2E Toxicity Analysis of Patient-Specific RPE Cells  
*Stephen Tsang*
- 7:54 a.m. Rap1 GTPase Improves RPE Barrier Integrity and Resists Choroidal Neovascularization  
*Mary Elizabeth Hartnett*
- 8:02 a.m. A New Quantitative Imaging Analysis Tool for Choroidal Neovascularization Area Measurements  
*Jennifer Kang-Mieler*
- 8:10 a.m. The Relationship Between the Aqueous Humor Concentrations of Inflammatory Cytokines and Posterior Vitreous Detachment in Age-Related Macular Degeneration  
*Yasuo Yanagi*
- 8:18 a.m. Angiogenesis Promotes Neurogenesis of the Retina  
*Kimberly Drenser*
- 8:26 a.m. Penetration and Transportation of Intravitreal Bevacizumab and Ranibizumab into the Optic Nerve of the Fellow Eye  
*Sophie Bakri*
- 8:34 a.m. Monocyte Trafficking in Retina: A Novel Target in Early Diabetic Retinopathy  
*Arup Das*
- 8:42 a.m. Circulating MicroRNAs of Aqueous and Vitreous as Putative Novel Diagnostic Biomarkers for Diabetic Retinopathy  
*Lawrence Morse*

## SESSION XI

### Macular Diseases and Surgery

*Moderator: Baruch Kuppermann*

*Moderator: Peter Kaiser*

- 8:50 a.m. Multimodal Imaging in Persistent Placoid Maculopathy  
*Lee Jampol*
- 8:58 a.m. Visual and Anatomic Results of the Macula Society Photodynamic Therapy (PDT) for Central Serous Chorioretinopathy (CSC) Retrospective Study  
*Jennifer Lim*
- 9:06 a.m. Evolution of Vitreomacular Detachment in Normal Subjects  
*Shoji Kishi*

- 9:14 a.m. Ocriplasmin Therapy for Pharmacologic Resolution of Symptomatic Vitreomacular Adhesion (VMA) in Clinical Candidates for Vitrectomy  
*Baruch Kuppermann*
- 9:22 a.m. Characterization of Full-Thickness Macular Holes (FTMH) in the MIVI-TRUST Program: An Optical Coherence Tomography (OCT) Analysis of Ocriplasmin Efficacy  
*Peter Kaiser*
- 9:30 a.m. Cystoid Dehydration and Closure of Macular Holes Without Surgery  
*Ronald Gentile*
- 9:38 a.m. Internal Limiting Membrane (ILM) Peeling Versus no Peeling for the Treatment of Idiopathic Full-Thickness Macular Hole (FTMH): A Systematic Review and an Individual Patient Data (IPD) Meta-Analysis  
*Noemi Lois*
- 9:46 a.m. Morphological Change of Inner Retinal Layer on Spectral Domain Optical Coherence Tomography following Macular Hole Surgery  
*Hyung Woo Kwak*
- 9:54 a.m. Changes of ILM Stiffness after Staining with Brilliant Blue and Indocyanine Green  
*Christos Haritoglou*
- 10:02 a.m. Assessment of Microarchitectural Retinal Dynamics of Epiretinal Membrane Surgery Utilizing Intraoperative Optical Coherence Tomography  
*Justis Ehlers*
- 10:10 a.m. One-year Results of the Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) Study: A Controlled Clinical Trial  
*Stephen Kim*
- 10:18 a.m. Efficiency of Silicone Oil Aspiration Across Gauges  
*Colin McCannel*
- 10:26 a.m. Spectral Domain Optical Coherence Tomography Patterns of Pseudophakic Cystoid Macular Edema  
*Michaella Goldstein*

10:34 a.m. Functional and Anatomical Outcomes of Tissue Plasminogen Activator (tPA) Treatment for Submacular Hemorrhage Associated with Exudative Macular Degeneration (ExAMD): A Comparative Analysis Between Intra-vitreous and Sub-retinal tPA injected Patients  
*Shlomit Schaal*

10:42 a.m. **Break**

**SESSION XII**  
**ROP/Miscellaneous**

*Moderator: Tim Olsen*

*Moderator: Judy Kim*

10:50 a.m. EcROP: Modeling the Region Specific Societal and Economic Impact of Evidence-Based Care for Retinopathy of Prematurity  
*Timothy Olsen*

10:58 a.m. Intravitreal Ranibizumab for Retinopathy of Prematurity  
*Caroline Bauman*

11:06 a.m. Hot or Rot: Black-market and Counterfeit Drugs  
*Robert Braunstein*

11:14 a.m. Factors Associated with Malpractice Outcomes of Retained Lens Fragments  
*Judy Kim*

11:22 a.m. Did Maculopathy Affect Degas' Sculpture?  
*Michael Marmor*

**SESSION XIII**

**Basic Science/Drug Delivery/Inherited Retinal Disease**

*Moderator: William Mieler*

*Moderator: Graham Holder*

11:30 a.m. Inner Retinal Oxygen Consumption in Hypoxia  
*Norman Blair*

11:38 a.m. Retinal Drug Discovery: Molecular Rheostats  
*Shalesh Kaushal*

11:46 a.m. Microglial Inhibition as a Therapeutic Strategy for Retinal Disease  
*Wai Wong*

- 11:54 p.m. Injectable Hydrogel for Sustained Drug Delivery for Retinal Diseases. A Viable Strategy?  
*Thomas Friberg*
- 12:02 p.m. Retinal Contributions to Refractive Development  
*Wallace Foulds*
- 12:10 p.m. Visual Outcomes of Cataract Extraction in Patients with Retinitis Pigmentosa  
*William Mieler*
- 12:18 p.m. The Clinical and Electrophysiological Features of Patients with Occult Maculopathy and Heterozygous RP1L1 Variants  
*Anthony Robson*
- 12:26 p.m. A Phenotype-Genotype Correlation Study of X-Linked Retinoschisis  
*Graham Holder*
- 12:34 p.m. Docking of Photoreceptor Outer Segments and Lack of Docking in Best Affected Subjects Shown by Three-dimensional Analysis of SD-OCT  
*Michael Abramoff*
- 12:42 p.m. **End of Session and Meeting**